Kura expects to price its public sale of 3.75 million shares at $16.00

Citigroup and Leerink are the bookrunners; JMP and Oppenheimer assist

By Devika Patel

Knoxville, Tenn., Oct. 28 – Kura Oncology, Inc. will sell 3.75 million common shares in its public offering with a greenshoe of 562,500 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $69 million of stock for the deal, which was announced on Oct. 20.

The shares will be sold at an expected price of $16.00 per share.

Citigroup and Leerink Partners are the bookrunners, and JMP Securities and Oppenheimer & Co. are the co-managers.

Proceeds will be used for clinical trials, research and preclinical development and general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of intellectual property.

The biopharmaceutical company is based in La Jolla, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.